Conjugate of ginsenoside compound k and glycol chitosan and an anti-tumor use thereof

Abstract

The present invention relates to a conjugate of ginsenoside compound K and glycol chitosan, a method for preparing the conjugate, and a pharmaceutical composition for treating cancer including the conjugate in a pharmaceutically acceptable carrier. The conjugate of ginsenoside compound K and glycol chitosan of the present invention has cancer cell-specific anticancer activity because of increased water solubility relative to ginsenoside compound K, formation of nanosized self-aggregates in an aqueous solution, stability at neutral pH and release of the ginsenoside compound K at acidic pH due to pH sensitivity, thus having excellent effects as a composition for treating cancer.

1 . A conjugate of ginsenoside compound K and glycol chitosan. 
     
     
         2 . The conjugate of  claim 1 , wherein the ginsenoside compound K is carboxylated. 
     
     
         3 . The conjugate of  claim 1 , wherein the conjugate is conjugated by an amide bond between carboxylated ginsenoside compound K and glycol chitosan. 
     
     
         4 . The conjugate of  claim 1 , wherein the conjugate comprises an ester linkage in binding sites. 
     
     
         5 . The conjugate of  claim 1 , wherein the conjugate forms self-aggregates in an aqueous solution. 
     
     
         6 . The conjugate of  claim 1 , wherein the conjugate releases the ginsenoside compound K at a pH between 4.0 and 6.0. 
     
     
         7 . The conjugate of  claim 1 , wherein the conjugate is maintained at least for 8 days without being decomposed at a pH between 7.0 and 8.0. 
     
     
         8 . A pharmaceutical composition comprising the conjugate of  claim 1 . 
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein the pharmaceutical composition is for treating cancer. 
     
     
         10 . The pharmaceutical composition of  claim 8 , which further comprises a pharmaceutically acceptable carrier. 
     
     
         11 . The pharmaceutical composition of  claim 9 , wherein the cancer is selected from the group consisting of esophageal cancer, stomach cancer, colorectal cancer, rectal cancer, oral cavity cancer, pharynx cancer, larynx cancer, lung cancer, colon cancer, breast cancer, uterine cervical cancer, endometrial cancer, ovarian cancer, prostate cancer, testis cancer, bladder cancer, kidney cancer, liver cancer, pancreatic cancer, bone cancer, connective tissue cancer, skin cancer, brain cancer, thyroid cancer, leukemia, Hodgkin's disease, lymphoma, multiple myeloma blood cancer. 
     
     
         12 . The pharmaceutical composition of  claim 9 , wherein the cancer is selected from the group consisting of colorectal cancer, liver cancer, and brain cancer. 
     
     
         13 . A method for preparing a conjugate of ginsenoside compound K and glycol chitosan, comprising:
 (a) carboxylating the ginsenoside compound K; and   (b) conjugating the carboxylated ginsenoside compound K and glycol chitosan.   
     
     
         14 . A method of  claim 13 , wherein the carboxylation is induced by succinic anhydride. 
     
     
         15 . A method of  claim 13 , wherein the conjugation is an amide bond. 
     
     
         16 . A method for treating cancer, comprising administering the pharmaceutical composition of  claim 8  to a subject.